The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now. On January 14, Reuters reported that investors ...

Biotech stocks tied to cancer, autoimmune and rare disease therapies gain attention as M&A activity boosts sector sentiment.